Savient Pharmaceuticals
Manufacturing · New Jersey, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
1 Tower Center Blvd Ste 1700, East Bruns...Phone Number
(732) 418-9300Website
www.savientpharma.comRevenue
$17.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Savient Pharmaceuticals
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients who do not respond to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA® and its uses from Duke University ("Duke"), which developed the recombinant uricase enzyme used in the manufacture of KRYSTEXXA®, and Mountain View Pharmaceuticals, Inc. ("MVP"), which developed the PEGylation technology used in the manufacture of KRYSTEXXA®. Each of MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology. Savient also owns or co-owns U.S. and foreign patents and patent applications, which together with the patents of MVP and Duke form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA®. In the U.S., Savient also supplies Oxandrin® (oxandRead more
Savient Pharmaceuticals Org Chart
RP
Chief Financial Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Savient Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Savient Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Savient Pharmaceuticals recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Savient Pharmaceuticals
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Savient Pharmaceuticals is spiking on competitors!
Click to see if Savient Pharmaceuticals had a recent Job posting/layoffs
Check if Savient Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Savient Pharmaceuticals launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Savient Pharmaceuticals has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Savient Pharmaceuticals
Compare insights from companies similar to Savient Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Savient Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Savient Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Savient Pharmaceuticals.
Savient Pharmaceuticals News & Media
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Savient Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients who do not respond to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA® and its uses from Duke Uni... Read More
